Conditions

Keywords

stage III adult Hodgkin lymphomastage IV adult Hodgkin lymphomarecurrent non-small cell lung cancerrecurrent adult Hodgkin lymphomarecurrent esophageal cancerstage III cutaneous T-cell non-Hodgkin lymphomastage IV cutaneous T-cell non-Hodgkin lymphomarecurrent cutaneous T-cell non-Hodgkin lymphomarecurrent small cell lung cancerstage III grade 1 follicular lymphomastage III grade 2 follicular lymphomastage III grade 3 follicular lymphomastage III adult diffuse small cleaved cell lymphomastage III adult diffuse mixed cell lymphomastage III adult diffuse large cell lymphomastage III adult immunoblastic large cell lymphomastage III adult lymphoblastic lymphomastage III adult Burkitt lymphomastage IV grade 1 follicular lymphomastage IV grade 2 follicular lymphomastage IV grade 3 follicular lymphomastage IV adult diffuse small cleaved cell lymphomastage IV adult diffuse mixed cell lymphomastage IV adult diffuse large cell lymphomastage IV adult immunoblastic large cell lymphomastage IV adult lymphoblastic lymphomastage IV adult Burkitt lymphomarecurrent grade 1 follicular lymphomarecurrent grade 2 follicular lymphomarecurrent grade 3 follicular lymphomarecurrent adult diffuse small cleaved cell lymphomarecurrent adult diffuse mixed cell lymphomarecurrent adult diffuse large cell lymphomarecurrent adult immunoblastic large cell lymphomarecurrent adult lymphoblastic lymphomarecurrent adult Burkitt lymphomastage III adult T-cell leukemia/lymphomastage IV adult T-cell leukemia/lymphomarecurrent adult T-cell leukemia/lymphomastage III mantle cell lymphomastage IV mantle cell lymphomarecurrent mantle cell lymphomarecurrent marginal zone lymphomarecurrent small lymphocytic lymphomastage III small lymphocytic lymphomastage III marginal zone lymphomastage IV small lymphocytic lymphomastage IV marginal zone lymphomaextranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissuenodal marginal zone B-cell lymphomasplenic marginal zone lymphoma

Study Arms (1)

Arm I

EXPERIMENTAL

Radiosensitization plus Radiotherapy. Topotecan hydrochloride, TOPO, NSC-609699; plus external-beam irradiation using linear accelerators with photon energies between 4 and 10 MV (electrons acceptable for the boost field).

Drug: topotecan hydrochlorideRadiation: low-LET electron therapyRadiation: low-LET photon therapy

Interventions

topotecan hydrochlorideDrug

Arm I

low-LET electron therapyRadiation

Arm I

low-LET photon therapy

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

DISEASE CHARACTERISTICS: * Microscopically confirmed solid tumor or lymphoma not potentially curable by conventional surgery or radiotherapy * Previously unirradiated disease scheduled to receive thoracic irradiation of up to 60 Gy, including pulmonary and esophageal tumors * No metastatic disease more effectively treated by systemic chemotherapy * No history of brain metastases PATIENT CHARACTERISTICS: * Age: 18 and over * Performance status: ECOG 0 or 1 * WBC at least 4,000 * ANC at least 1,500 * Platelets at least 100,000 * Bilirubin no greater than 1.5 mg/dL * Creatinine no greater than 1.5 mg/dL * Calcium no greater than 11.0 mg/dL * No pregnant or nursing women * Pregnancy test required, as appropriate * Effective contraception required of fertile patient PRIOR CONCURRENT THERAPY: * At least 4 weeks since chemotherapy (6 weeks since nitrosoureas and mitomycin) and recovered * At least 4 weeks since radiotherapy and recovered

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

National Cancer Institute (NCI)
NIHlead

Study Sites (1)

University of Wisconsin Comprehensive Cancer Center

Madison, Wisconsin, 53792, United States

Related Publications (1)

Forouzannia A, Schiller J, Berlin J, Hutson P, Boothman D, Storer B, Wilding G, Mehta M. A phase I study of Topotecan, as a radiosensitizer, for thoracic malignancies. Lung Cancer. 2004 Apr;44(1):111-9. doi: 10.1016/j.lungcan.2003.10.005.
PMID: 15013589RESULT

MeSH Terms

Conditions

Esophageal NeoplasmsLung NeoplasmsLymphomaHodgkin DiseaseCarcinoma, Non-Small-Cell LungLymphoma, T-Cell, CutaneousSmall Cell Lung CarcinomaLymphoma, FollicularLymphoma, Non-HodgkinLymphoma, Large B-Cell, DiffuseLymphoma, Large-Cell, ImmunoblasticPrecursor Cell Lymphoblastic Leukemia-LymphomaBurkitt LymphomaPrecursor T-Cell Lymphoblastic Leukemia-LymphomaLymphoma, Mantle-CellLymphoma, B-Cell, Marginal Zone

Study Officials

George Wilding, MD
University of Wisconsin, Madison
STUDY CHAIR

Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or Lymphoma

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

Primary Completion

Study Completion

First Posted

Conditions

Keywords

Study Arms (1)

Arm I

Interventions

Eligibility Criteria

Sponsors & Collaborators

Study Sites (1)

Related Publications (1)

MeSH Terms

Conditions

Study Officials

Enrollment

Study Design

Study Record Dates

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

Primary Completion

Study Completion

First Posted

Conditions

Keywords

Study Arms (1)

Arm I

Interventions

Eligibility Criteria

Sponsors & Collaborators

Study Sites (1)

Related Publications (1)

MeSH Terms

Conditions

Study Officials

Enrollment

Study Design

Study Record Dates

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Source record

Locations